157 related articles for article (PubMed ID: 31653510)
1. A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study.
O'Cearbhaill RE; Deng W; Chen LM; Lucci JA; Behbakht K; Spirtos NM; Muller CY; Benigno BB; Powell MA; Berry E; Tewari KS; Hanjani P; Lankes HA; Aghajanian C; Sabbatini PJ
Gynecol Oncol; 2019 Dec; 155(3):393-399. PubMed ID: 31653510
[TBL] [Abstract][Full Text] [Related]
2. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer.
Sabbatini PJ; Ragupathi G; Hood C; Aghajanian CA; Juretzka M; Iasonos A; Hensley ML; Spassova MK; Ouerfelli O; Spriggs DR; Tew WP; Konner J; Clausen H; Abu Rustum N; Dansihefsky SJ; Livingston PO
Clin Cancer Res; 2007 Jul; 13(14):4170-7. PubMed ID: 17634545
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinoma.
Smaletz O; Diz MD; do Carmo CC; Sabbaga J; Cunha-Junior GF; Azevedo SJ; Maluf FC; Barrios CH; Costa RL; Fontana AG; Madrigal V; Wainstein AJ; Yeda FP; Alves VA; Moro AM; Blasbalg R; Scott AM; Hoffman EW
Gynecol Oncol; 2015 Aug; 138(2):272-7. PubMed ID: 26026738
[TBL] [Abstract][Full Text] [Related]
4. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.
Vergote I; Scambia G; O'Malley DM; Van Calster B; Park SY; Del Campo JM; Meier W; Bamias A; Colombo N; Wenham RM; Covens A; Marth C; Raza Mirza M; Kroep JR; Ma H; Pickett CA; Monk BJ;
Lancet Oncol; 2019 Jun; 20(6):862-876. PubMed ID: 31076365
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study.
Tew WP; Sill MW; Walker JL; Secord AA; Bonebrake AJ; Schilder JM; Stuckey A; Rice L; Tewari KS; Aghajanian CA
Gynecol Oncol; 2018 Nov; 151(2):257-263. PubMed ID: 30177462
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
Cohn DE; Sill MW; Walker JL; O'Malley D; Nagel CI; Rutledge TL; Bradley W; Richardson DL; Moxley KM; Aghajanian C
Gynecol Oncol; 2017 Sep; 146(3):477-483. PubMed ID: 28756871
[TBL] [Abstract][Full Text] [Related]
7. Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?
Sioulas VD; Schiavone MB; Kadouri D; Zivanovic O; Roche KL; O'Cearbhaill R; Abu-Rustum NR; Levine DA; Sonoda Y; Gardner GJ; Leitao MM; Chi DS
Gynecol Oncol; 2017 Apr; 145(1):15-20. PubMed ID: 28238354
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study.
Alvarez RD; Sill MW; Davidson SA; Muller CY; Bender DP; DeBernardo RL; Behbakht K; Huh WK
Gynecol Oncol; 2014 Jun; 133(3):433-8. PubMed ID: 24708919
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.
Vergote I; Coens C; Nankivell M; Kristensen GB; Parmar MKB; Ehlen T; Jayson GC; Johnson N; Swart AM; Verheijen R; McCluggage WG; Perren T; Panici PB; Kenter G; Casado A; Mendiola C; Stuart G; Reed NS; Kehoe S; ;
Lancet Oncol; 2018 Dec; 19(12):1680-1687. PubMed ID: 30413383
[TBL] [Abstract][Full Text] [Related]
10. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer.
Chianese-Bullock KA; Irvin WP; Petroni GR; Murphy C; Smolkin M; Olson WC; Coleman E; Boerner SA; Nail CJ; Neese PY; Yuan A; Hogan KT; Slingluff CL
J Immunother; 2008 May; 31(4):420-30. PubMed ID: 18391753
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes of patients with recurrent ovarian cancer treated with a polyvalent vaccine with bevacizumab combination.
Kahn RM; Ragupathi G; Zhou QC; Iasonos A; Kravetz S; Hensley ML; Konner JA; Makker V; Tew WP; Aghajanian C; Sabbatini PJ; O'Cearbhaill RE
Cancer Immunol Immunother; 2023 Jan; 72(1):183-191. PubMed ID: 35779095
[TBL] [Abstract][Full Text] [Related]
12. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
du Bois A; Kristensen G; Ray-Coquard I; Reuss A; Pignata S; Colombo N; Denison U; Vergote I; Del Campo JM; Ottevanger P; Heubner M; Minarik T; Sevin E; de Gregorio N; Bidziński M; Pfisterer J; Malander S; Hilpert F; Mirza MR; Scambia G; Meier W; Nicoletto MO; Bjørge L; Lortholary A; Sailer MO; Merger M; Harter P;
Lancet Oncol; 2016 Jan; 17(1):78-89. PubMed ID: 26590673
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of BRCA1/2 pathogenic variants in ovarian cancer cluster region in patients with primary peritoneal, epithelial ovarian, and fallopian tube cancer.
Ha HI; Park EY; Eoh KJ; Lee YJ; Seo SS; Kang S; Park SY; Lim MC
Gynecol Oncol; 2022 Feb; 164(2):415-420. PubMed ID: 34924242
[TBL] [Abstract][Full Text] [Related]
14. Validation of Revised FIGO Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum Based on a Single Histological Type.
Toptas T; Pestereli E; Erol O; Bozkurt S; Erdogan G; Simsek T
Int J Gynecol Cancer; 2016 Jul; 26(6):1012-9. PubMed ID: 27206284
[TBL] [Abstract][Full Text] [Related]
15. Exploring the added value of hospital-registry data for showing local service outcomes: cancers of the ovary, fallopian tube and peritoneum.
Roder D; Davy M; Selva-Nayagam S; Paramasivam S; Adams J; Keefe D; Miller C; Powell K; Fusco K; Buranyi-Trevarton D; Oehler MK
BMJ Open; 2019 Feb; 9(2):e024036. PubMed ID: 30782891
[TBL] [Abstract][Full Text] [Related]
16. Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study.
Huang CS; Yu AL; Tseng LM; Chow LWC; Hou MF; Hurvitz SA; Schwab RB; L Murray J; Chang HK; Chang HT; Chen SC; Kim SB; Hung JT; Ueng SH; Lee SH; Chen CC; Rugo HS
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32718986
[TBL] [Abstract][Full Text] [Related]
17. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.
Slovin SF; Ragupathi G; Musselli C; Fernandez C; Diani M; Verbel D; Danishefsky S; Livingston P; Scher HI
Cancer Immunol Immunother; 2005 Jul; 54(7):694-702. PubMed ID: 15726361
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001).
Konstantinopoulos PA; Brady WE; Farley J; Armstrong A; Uyar DS; Gershenson DM
Gynecol Oncol; 2018 Jul; 150(1):9-13. PubMed ID: 29739622
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a Simple and Safe Tumor Drilling Technique to Potentiate the Effect of Intraperitoneal Chemotherapy in the Treatment of Recurrent Epithelial Ovarian, Tubal, and Peritoneal Cancer: A Matched Retrospective Cohort Study.
Chao WT; Chien CH; Lai CR; Wu HJ; Chuang CM
Cancer Control; 2019; 26(1):1073274819863778. PubMed ID: 31343898
[TBL] [Abstract][Full Text] [Related]
20. Use of a multi-drug regimen gemcitabine, 5-fluorouracil, irinotecan, cisplatin, bevacizumab, docetaxel, and cyclophosphamide (GFIP/BDC) for heavily pretreated relapsed epithelial ovarian, fallopian tube and primary peritoneal cancer.
Cohen S; Schwartz M; Dottino P; Beddoe AM
J Ovarian Res; 2019 Apr; 12(1):36. PubMed ID: 31027500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
